Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Science in Medicine

  • 118 Articles
  • 0 Posts
  • ← Previous
  • 1
  • 2
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • Next →
The evolving biology and treatment of prostate cancer
Russel S. Taichman, Robert D. Loberg, Rohit Mehra, Kenneth J. Pienta
Russel S. Taichman, Robert D. Loberg, Rohit Mehra, Kenneth J. Pienta
View: Text | PDF

The evolving biology and treatment of prostate cancer

  • Text
  • PDF
Abstract

Since the effectiveness of androgen deprivation for treatment of advanced prostate cancer was first demonstrated, prevention strategies and medical therapies for prostate cancer have been based on understanding the biologic underpinnings of the disease. Prostate cancer treatment is one of the best examples of a systematic therapeutic approach to target not only the cancer cells themselves, but the microenvironment in which they are proliferating. As the population ages and prostate cancer prevalence increases, challenges remain in the diagnosis of clinically relevant prostate cancer as well as the management of the metastatic and androgen-independent metastatic disease states.

Authors

Russel S. Taichman, Robert D. Loberg, Rohit Mehra, Kenneth J. Pienta

×

Angiogenesis modulates adipogenesis and obesity
Yihai Cao
Yihai Cao
View: Text | PDF

Angiogenesis modulates adipogenesis and obesity

  • Text
  • PDF
Abstract

Substantial evidence shows that neoplastic and nonneoplastic tissue growth is dependent on angiogenesis. Neovascularization and adipogenesis are temporally and spatially coupled processes during prenatal life and they continue to reciprocally interact via paracrine signaling systems throughout adult life. Activated adipocytes produce multiple angiogenic factors including leptin, angiopoietins, HGF, GM-CSF, VEGF, FGF-2, and TGF-β, which either alone or collectively stimulate neovascularization during fat mass expansion. Thus antiangiogenic agents provide a novel therapeutic option for prevention and treatment of human obesity and its related disorders.

Authors

Yihai Cao

×

MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets
Eva van Rooij, Eric N. Olson
Eva van Rooij, Eric N. Olson
View: Text | PDF

MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets

  • Text
  • PDF
Abstract

MicroRNAs act as negative regulators of gene expression by inhibiting the translation or promoting the degradation of target mRNAs. Recent studies have revealed key roles of microRNAs as regulators of the growth, development, function, and stress responsiveness of the heart, providing glimpses of undiscovered regulatory mechanisms and potential therapeutic targets for the treatment of heart disease.

Authors

Eva van Rooij, Eric N. Olson

×

Lymphocytes, neuropeptides, and genes involved in alopecia areata
Amos Gilhar, Ralf Paus, Richard S. Kalish
Amos Gilhar, Ralf Paus, Richard S. Kalish
View: Text | PDF

Lymphocytes, neuropeptides, and genes involved in alopecia areata

  • Text
  • PDF
Abstract

Many lessons in autoimmunity — particularly relating to the role of immune privilege and the interplay between genetics and neuroimmunology — can be learned from the study of alopecia areata, the most common cause of inflammation-induced hair loss. Alopecia areata is now understood to represent an organ-restricted, T cell–mediated autoimmune disease of hair follicles. Disease induction is associated with collapse of hair follicle immune privilege in both humans and in animal models. Here, the role of HLA associations, other immunogenetic factors, and neuroendocrine parameters in alopecia areata pathogenesis are reviewed. This instructive and clinically significant model disease deserves more widespread interest in the immunology community.

Authors

Amos Gilhar, Ralf Paus, Richard S. Kalish

×

Genomics and the evolution, pathogenesis, and diagnosis of tuberculosis
Joel D. Ernst, Giraldina Trevejo-Nuñez, Niaz Banaiee
Joel D. Ernst, Giraldina Trevejo-Nuñez, Niaz Banaiee
View: Text | PDF

Genomics and the evolution, pathogenesis, and diagnosis of tuberculosis

  • Text
  • PDF
Abstract

Tuberculosis kills nearly 2 million people annually, and current approaches to tuberculosis control are expensive, have limited efficacy, and are vulnerable to being overcome by extensively drug-resistant strains of Mycobacterium tuberculosis. Determination of the genome sequence of M. tuberculosis has revolutionized tuberculosis research, contributed to major advances in the understanding of the evolution and pathogenesis of M. tuberculosis, and facilitated development of new diagnostic tests with increased specificity for tuberculosis. In this review, we describe some of the major progress in tuberculosis research that has resulted from knowledge of the genome sequence and note some of the problems that remain unsolved.

Authors

Joel D. Ernst, Giraldina Trevejo-Nuñez, Niaz Banaiee

×

Gene therapy for severe combined immunodeficiency: are we there yet?
Marina Cavazzana-Calvo, Alain Fischer
Marina Cavazzana-Calvo, Alain Fischer
View: Text | PDF

Gene therapy for severe combined immunodeficiency: are we there yet?

  • Text
  • PDF
Abstract

Inherited and acquired diseases of the hematopoietic system can be cured by allogeneic hematopoietic stem cell transplantation. This treatment strategy is highly successful when an HLA-matched sibling donor is available, but if not, few therapeutic options exist. Gene-modified, autologous bone marrow transplantation can circumvent the severe immunological complications that occur when a related HLA-mismatched donor is used and thus represents an attractive alternative. In this review, we summarize the advantages and limitations associated with the use of gene therapy to cure SCID. Insertional mutagenesis and technological improvements aimed at increasing the safety of this strategy are also discussed.

Authors

Marina Cavazzana-Calvo, Alain Fischer

×

Adoptive T cell therapy for cancer in the clinic
Carl H. June
Carl H. June
View: Text | PDF

Adoptive T cell therapy for cancer in the clinic

  • Text
  • PDF
Abstract

The transfusion of lymphocytes, referred to as adoptive T cell therapy, is being tested for the treatment of cancer and chronic infections. Adoptive T cell therapy has the potential to enhance antitumor immunity, augment vaccine efficacy, and limit graft-versus-host disease. This form of personalized medicine is now in various early- and late-stage clinical trials. These trials are currently testing strategies to infuse tumor-infiltrating lymphocytes, CTLs, Th cells, and Tregs. Improved molecular biology techniques have also increased enthusiasm and feasibility for testing genetically engineered T cells. The current status of the field and prospects for clinical translation are reviewed herein.

Authors

Carl H. June

×

APC-derived cytokines and T cell polarization in autoimmune inflammation
Ilona Gutcher, Burkhard Becher
Ilona Gutcher, Burkhard Becher
View: Text | PDF

APC-derived cytokines and T cell polarization in autoimmune inflammation

  • Text
  • PDF
Abstract

T cell–mediated autoimmune diseases such as multiple sclerosis and rheumatoid arthritis are driven by autoaggressive Th cells. The pathogenicity of such Th cells has, in the past, been considered to be dictated by their cytokine polarization profile. The polarization of such effector T cells relies critically upon the actions of cytokines secreted by APCs. While Th1 polarization has long been associated with the pathogenesis of autoimmune diseases, recent data obtained in gene-targeted mice and the discovery of Th17 cell involvement in autoimmunity conflict with this hypothesis. In light of these recent developments, we discuss in this review the actions of APC-derived cytokines and their emerging roles in T cell polarization in the context of autoimmune inflammatory responses.

Authors

Ilona Gutcher, Burkhard Becher

×

gp130 receptor ligands as potential therapeutic targets for obesity
Mark A. Febbraio
Mark A. Febbraio
View: Text | PDF

gp130 receptor ligands as potential therapeutic targets for obesity

  • Text
  • PDF
Abstract

Obesity and its related cluster of pathophysiologic conditions including insulin resistance, glucose intolerance, dyslipidemia, and hypertension are recognized as growing threats to world health. It is now estimated that 10% of the world’s population is overweight or obese. As a result, new therapeutic options for the treatment of obesity are clearly warranted. Recent research has focused on the role that gp130 receptor ligands may play as potential therapeutic targets in obesity. One cytokine in particular, ciliary neurotrophic factor (CNTF), acts both centrally and peripherally and mimics the biologic actions of the appetite control hormone leptin, but unlike leptin, CNTF appears to be effective in obesity and as such may have therapeutic potential. In addition, CNTF suppresses inflammatory signaling cascades associated with lipid accumulation in liver and skeletal muscle. This review examines the potential role of gp130 receptor ligands as part of a therapeutic strategy to treat obesity.

Authors

Mark A. Febbraio

×

Sickle cell disease: old discoveries, new concepts, and future promise
Paul S. Frenette, George F. Atweh
Paul S. Frenette, George F. Atweh
View: Text | PDF

Sickle cell disease: old discoveries, new concepts, and future promise

  • Text
  • PDF
Abstract

The discovery of the molecular basis of sickle cell disease was an important landmark in molecular medicine. The modern tools of molecular and cellular biology have refined our understanding of its pathophysiology and facilitated the development of new therapies. In this review, we discuss some of the important advances in this field and the impediments that limit the impact of these advances.

Authors

Paul S. Frenette, George F. Atweh

×
  • ← Previous
  • 1
  • 2
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • Next →

No posts were found with this tag.

Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts